5. Oxylipins reveal a lot about cardiometabolic diseases

5. Oxylipins reveal a lot about cardiometabolic diseases

Summary of the key fact

Metabolic syndrome is a major public health problem. It affects nearly a quarter of the world's population and substantially increases the risk of cardiometabolic diseases such as cardiovascular disease and type 2 diabetes. The clinical diagnosis of metabolic syndrome is based on the presence of at least three criteria: obesity, hypertension, dyslipidemia, or hyperglycemia. Although easy to implement clinically, this diagnosis provides a relatively crude and late level of prediction of the risk of cardiometabolic diseases. What if oxylipins paved the way for a better diagnosis ? Indeed, oxylipins are a large family of signaling lipids that regulate many biological processes underlying cardiometabolic disorders such as inflammation or blood coagulation. Researchers from the Human Nutrition Unit (UNH) conducted a detailed analysis of these lipids in the plasma of patients with metabolic syndrome. The analysis thus made it possible to identify a specific signature of 23 oxylipins, validated in two independent population studies. Associated with clinical diagnosis, this oxylipin signature could allow for more precise and early characterization of cardiometabolic drifts and thus better stratification and management of at-risk patients.

DOI : 10.3390/ijms231911688

Contact : Cécile GLADINE